{"id":3672,"date":"2021-02-03T22:20:19","date_gmt":"2021-02-04T06:20:19","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=3672"},"modified":"2021-02-03T22:20:19","modified_gmt":"2021-02-04T06:20:19","slug":"the-basis-of-a-more-contagious-501y-v1-variant-of-sars-cov-2","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/02\/03\/the-basis-of-a-more-contagious-501y-v1-variant-of-sars-cov-2\/","title":{"rendered":"The Basis of a More Contagious 501Y.V1 Variant of SARS-COV-2"},"content":{"rendered":"<p><i>[Pre-print, not peer-reviewed]<\/i> The receptor binding domain (RBD) of the 501Y.V1 SARS-CoV-2 variant (first identified in the UK) has around a 10-times higher binding affinity for human ACE2 than the RBD of the parent N501 strain, suggesting a potential mechanism for the higher rate of contagiousness observed with this strain. Sera collected from individuals immunized with the Pfizer-BioNTech vaccine could block the binding of Y501-RBD to ACE2, albeit to a slightly lesser degree than wild type. The therapeutic antibody bamlanivimab, however, bound the Y501-RBD as efficiently as the N501-RBD.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p><i>Zhang et al. (Feb 2, 2021). The Basis of a More Contagious 501Y.V1 Variant of SARS-COV-2. BioRxiv. <\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.02.02.428884\">https:\/\/doi.org\/10.1101\/2021.02.02.428884<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] The receptor binding domain (RBD) of the 501Y.V1 SARS-CoV-2 variant (first identified in the UK) has around a 10-times higher binding affinity for human ACE2 than the RBD of the parent N501 strain, suggesting a potential mechanism for the higher rate of contagiousness observed with this strain. Sera collected from individuals immunized&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/02\/03\/the-basis-of-a-more-contagious-501y-v1-variant-of-sars-cov-2\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[159],"topic":[31],"class_list":["post-3672","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-variants","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=3672"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3672\/revisions"}],"predecessor-version":[{"id":3673,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3672\/revisions\/3673"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=3672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=3672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=3672"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=3672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}